Interleukin-6 inhibition in the treatment of autoinflammatory diseases

Koga, Tomohiro; Kawakami, Atsushi

doi:10.3389/fimmu.2022.956795

Cited by 17 publications

(15 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 10 Since the involvement of interleukin-6-mediated cell signaling is well recognized in TRAPS, tocilizumab has been regarded as a treatment option. 11 12 Successful treatment with tocilizumab in patients with TRAPS have been reported in a few case reports where a patient unresponsive to anakinra and etanercept successfully responded to tocilizumab treatment, 12 a patient unresponsive to infliximab 13 and etanercept showed clinical improvement by tocilizumab treatment, 14 and a mutation-negative patient with TRAPS unresponsive to colchicine and etanercept was effectively treated by tocilizumab. 15 However, our case is the first in which tocilizumab was administered first without a previous trial of other biologics and was found to be effective for the longest duration–more than 5 years–documented so far in the literature.…”

Section: Discussionmentioning

confidence: 99%

The First Case of a Korean Patient with a Mutation-Confirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome

Lee,

Baek,

Lee

et al. 2024

Yonsei Med J

View full text Add to dashboard Cite

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS, OMIM: #142680) is a rare autoinflammatory disease (AID) with recurrent febrile episodes. To our knowledge, we report herein the first case of a patient with TRAPS in South Korea whose symptoms included fever, arthralgia, abdominal pain, rash, myalgia, cough, and lymphadenopathy. A pathogenic de novo mutation, c.175T>C (p.Cys59Arg), in the tumor necrosis factor receptor superfamily member 1A ( TNFRSF1A ) gene, was confirmed by gene sequencing. The patient has been with tocilizumab (an interleukin-6 inhibitor); tocilizumab administration every other week has completely alleviated the patient’s symptoms. Our report further expands the clinical spectrum of patients with TRAPS and reaffirms the use of tocilizumab as a viable alternative treatment option for those patients who are unsatisfactorily responsive to other commonly used biologics, such as canakinumab, anakinra, infliximab, and etanercept. Furthermore, our report may aid in increasing awareness about the existence of mutation-confirmed TRAPS in South Korea in addition to emphasizing the importance of actively pursuing genetic testing to correctly diagnose rare AID.

show abstract

Section: Discussionmentioning

confidence: 99%

The First Case of a Korean Patient with a Mutation-Confirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome

Lee,

Baek,

Lee

et al. 2024

Yonsei Med J

View full text Add to dashboard Cite

show abstract

“…By selectively blocking immune mediators, these drugs effectively suppress disease activity, prevent amyloidosis, and halt organ damage ( 2 ). Since IL-6 levels may be elevated in trap ( 21 ), it has been hypothesized that monoclonal antibodies against the interleukin-6 (IL-6) receptor, may be relieve clinical symptoms ( 22 ).…”

Section: Discussionmentioning

confidence: 99%

Tumor necrosis factor receptor-associated cycle syndrome: a case report and literature review

Li,

Jing,

Zhang

et al. 2023

Front. Pediatr.

View full text Add to dashboard Cite

Recurring episodes of fever characterize tumor necrosis factor receptor-associated periodic syndrome (TRAPS) which is autosomal dominant. The primary symptoms of patients with TRAPS include prolonged fever, abdominal pain, muscle pain, and skin rashes. The prevalence of TRAPS appeared higher in Western countries than in Asian countries. Herein, we present the case of a 13-year-old girl who experienced intermittent fever for 8 years, with episodes that occur every 2 years. The patient demonstrated periodic fever, headache, vomiting, rash, and elevated inflammatory marker levels during the disease course. A heterozygous C55Y mutation was identified via a direct DNA sequencing of her genomic DNA. This mutation is located in exon 4 of TNFRSF1A. Genetic studies of her sister and mother revealed that they possessed the C55Y heterozygous mutation without demonstrating any clinical signs, while the father did not. Further, we conducted a thorough assessment of the literature and compiled the information from the eight TRAPS case series.

show abstract

“…11. Изучить возможности расширения показаний для терапии ОКЗ, учитывая позитивный опыт применения ингибиторов ИЛ-6 (ТЦЗ) для лечения гигантоклеточного артериита [131][132][133], артериита Такаясу [134], ювенильного идиопатического артрита [135], болезни Стилла взрослых [136], ранней системной склеродермии [112,113], аутовоспалительных заболеваний (семейная средиземноморская лихорадка, болезнь Бехчета, периодический синдром, ассоциированный с рецептором ФНО) [137], гипервоспалительных синдромов [120,138,139], включая синдром активации макрофагов, гемафагоцитарный лимфогистиоцитоз, CAR-T (Chimeric antigen receptor) клеточную терапию, COVID-19, синдром PICS (persistent infl ammation, immunosuppression, syndrome catabolism).…”

Section: перспективы и программа исследованийunclassified

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)

Насонов

Feist

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic immune-mediated rheumatic diseases (IMRDs) manifested with progressive destruction of joints, systemic inflammation of visceral organs and a wide range of co-morbidities associated with chronic inflammation. Among the cytokines involved in the pathogenesis of RA and certain other IMRDs, the role of interleukin (IL) 6 is of special interest. The introduction of mAbs tocilizumab (TCZ) and later sarilumab (SAR), both blocking the receptor of this cytokine, into clinical practice was an important achievement in the treatment of IIRDs at the beginning of the 21st century. As a novel approach in the treatment of RA, the humanized mAb against IL-6 olokizumab (OKZ) is in development by the Russian company R-PHARM under the license agreement with UCB Pharma. The review examines new data on efficacy and safety of OKZ in RA and the prospects of its use in rheumatology

show abstract

Interleukin-6 inhibition in the treatment of autoinflammatory diseases

Cited by 17 publications

References 51 publications

The First Case of a Korean Patient with a Mutation-Confirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome

The First Case of a Korean Patient with a Mutation-Confirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome

Tumor necrosis factor receptor-associated cycle syndrome: a case report and literature review

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)

Contact Info

Product

Resources

About